<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134402">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01782079</url>
  </required_header>
  <id_info>
    <org_study_id>LB - 001</org_study_id>
    <nct_id>NCT01782079</nct_id>
  </id_info>
  <brief_title>L. Brevis CD2 Strain Persistence in Oral Cavity</brief_title>
  <official_title>Assessment of Probiotic Lactobacillus Brevis CD2 Strain Persistence in Oral Cavity. A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to select the optimal conditions for quantification in the oral
      cavity of Lactobacillus brevis CD2, a probiotic strain contained in a commercially available
      dietary supplement and to assess its persistency after oral administration. Different sets
      of primers for L. brevis detection will be tested in real-time PCR reactions to find optimal
      amplification efficiency and target specificity. Primers ability in the identification of L.
      brevis DNA will be assessed in a pilot study conducted on 12 healthy volunteers clinically
      free of oral pathologies. The subjects will take 3 tablets/day for 3 days and one tablet on
      the 4th day. Clinical samples (dorsal surface of tongue, first molar, vestibular fornix and
      saliva) will be collected at baseline (before beginning the trial), at T0 (in the morning
      before the assumption of the last tablet) and 3, 6, and 9 hours after taking the last
      tablet. The quantities of L. brevis DNA will be compared to the total number of bacteria
      present in the samples. The activity of the enzyme arginine deiminase, responsible for oral
      pH homeostasis (particularly abundant in the CD2 strain) will be also assessed in the saliva
      samples before and after treatment, by HPLC measurements.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Quantification and persistency of Lactobacillus brevis CD2 after oral administration</measure>
    <time_frame>4 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mucosal surface colonization in various mouth sites will be assessed by measuring the number of bacteria by Real Time PCR. Quantities of L. brevis DNA will be compared to the total number of bacteria present in the samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arginine deiminase activity</measure>
    <time_frame>4 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Enzyme activity, measured as the amount of citrulline formed per minute in the assay conditions, will be determined in saliva samples by HPLC measurements.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Oral Health</condition>
  <arm_group>
    <arm_group_label>L. brevis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L. brevis</intervention_name>
    <arm_group_label>L. brevis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Healthy subjects with no oral cavity pathologies

          -  Written informed consent

        Exclusion Criteria:

          -  Patients with oral diseases

          -  Patients with systemic diseases

          -  Celiac patients or subjects affected by allergic reactions to soy proteins

          -  Use of antibiotics or other probiotics
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universit√† La Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 22, 2013</lastchanged_date>
  <firstreceived_date>January 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Luciana Mosca, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lactobacillus brevis</keyword>
  <keyword>Oral health</keyword>
  <keyword>Bacterial adhesion</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
